Outcomes of Pituitary Radiation for Cushing's Disease

Natasha Ironside; Ching Jen Chen; Cheng Chia Lee; Daniel Trifiletti; Mary Lee Vance; Jason P. Sheehan

doi:10.1016/j.ecl.2018.01.002

Outcomes of Pituitary Radiation for Cushing's Disease

Natasha Ironside, Ching Jen Chen, Cheng Chia Lee, Daniel Trifiletti, Mary Lee Vance, Jason P. Sheehan

Radiation Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

6 Scopus citations

Abstract

Achievement of biochemical remission with preservation of normal pituitary function is the goal of treatment for Cushing's disease. For patients with persistent or recurrent Cushing's disease after transsphenoidal resection, radiation therapy may be a safe and effective treatment. Stereotactic radiosurgery is favored over conventional fractionated external beam radiation. Hormonal recurrence rates range from 0% to 36% at 8 years after treatment. Tumor control rates are high. New pituitary hormone deficiency is the most common adverse effect after stereotactic radiosurgery and external beam radiation. The effects of radiation planning optimization and use of adjuvant medication on endocrine remission rates warrant investigation.

Original language	English (US)
Title of host publication	Endocrinology and Metabolism Clinics of North America
Editors	Adriana G. Ioachimescu
Publisher	W.B. Saunders
Pages	349-365
Number of pages	17
Volume	47
Edition	2
ISBN (Print)	9780323612937
DOIs	https://doi.org/10.1016/j.ecl.2018.01.002
State	Published - Jun 1 2018

Keywords

Cushing's disease
Endocrine
Radiation therapy
Remission
Stereotactic radiosurgery

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.ecl.2018.01.002

Cite this

@inbook{0ba70988135b4d45980e13d74ea92029,

title = "Outcomes of Pituitary Radiation for Cushing's Disease",

abstract = "Achievement of biochemical remission with preservation of normal pituitary function is the goal of treatment for Cushing's disease. For patients with persistent or recurrent Cushing's disease after transsphenoidal resection, radiation therapy may be a safe and effective treatment. Stereotactic radiosurgery is favored over conventional fractionated external beam radiation. Hormonal recurrence rates range from 0% to 36% at 8 years after treatment. Tumor control rates are high. New pituitary hormone deficiency is the most common adverse effect after stereotactic radiosurgery and external beam radiation. The effects of radiation planning optimization and use of adjuvant medication on endocrine remission rates warrant investigation.",

keywords = "Cushing's disease, Endocrine, Radiation therapy, Remission, Stereotactic radiosurgery",

author = "Natasha Ironside and Chen, {Ching Jen} and Lee, {Cheng Chia} and Daniel Trifiletti and Vance, {Mary Lee} and Sheehan, {Jason P.}",

year = "2018",

month = jun,

day = "1",

doi = "10.1016/j.ecl.2018.01.002",

language = "English (US)",

isbn = "9780323612937",

volume = "47",

pages = "349--365",

editor = "Ioachimescu, {Adriana G.}",

booktitle = "Endocrinology and Metabolism Clinics of North America",

publisher = "W.B. Saunders",

edition = "2",

}

TY - CHAP

T1 - Outcomes of Pituitary Radiation for Cushing's Disease

AU - Ironside, Natasha

AU - Chen, Ching Jen

AU - Lee, Cheng Chia

AU - Trifiletti, Daniel

AU - Vance, Mary Lee

AU - Sheehan, Jason P.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Achievement of biochemical remission with preservation of normal pituitary function is the goal of treatment for Cushing's disease. For patients with persistent or recurrent Cushing's disease after transsphenoidal resection, radiation therapy may be a safe and effective treatment. Stereotactic radiosurgery is favored over conventional fractionated external beam radiation. Hormonal recurrence rates range from 0% to 36% at 8 years after treatment. Tumor control rates are high. New pituitary hormone deficiency is the most common adverse effect after stereotactic radiosurgery and external beam radiation. The effects of radiation planning optimization and use of adjuvant medication on endocrine remission rates warrant investigation.

AB - Achievement of biochemical remission with preservation of normal pituitary function is the goal of treatment for Cushing's disease. For patients with persistent or recurrent Cushing's disease after transsphenoidal resection, radiation therapy may be a safe and effective treatment. Stereotactic radiosurgery is favored over conventional fractionated external beam radiation. Hormonal recurrence rates range from 0% to 36% at 8 years after treatment. Tumor control rates are high. New pituitary hormone deficiency is the most common adverse effect after stereotactic radiosurgery and external beam radiation. The effects of radiation planning optimization and use of adjuvant medication on endocrine remission rates warrant investigation.

KW - Cushing's disease

KW - Endocrine

KW - Radiation therapy

KW - Remission

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85045078157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045078157&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2018.01.002

DO - 10.1016/j.ecl.2018.01.002

M3 - Chapter

C2 - 29754636

AN - SCOPUS:85045078157

SN - 9780323612937

VL - 47

SP - 349

EP - 365

BT - Endocrinology and Metabolism Clinics of North America

A2 - Ioachimescu, Adriana G.

PB - W.B. Saunders

ER -

Outcomes of Pituitary Radiation for Cushing's Disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this